Announcement on behalf of OBIGEN:TFDA Approves IND application for Two Pivotal Phase III Studies of OBI-858

Date of occurrence of the event:2025/08/22 New drug name or code: OBI-858 Novel Botulinum Neurotoxin Indication:OBI-858 is a novel botulinum neurotoxin (BoNT) developed using OBIGEN’s proprietary bacteria, intended for both aesthetic and therapeutic applications. The product was discovered and developed in Taiwan and possessed a unique molecular weight. It has been granted patents in multiple […]